Xarelto can cause uncontrollable bleeding, heart attacks and stroke. Many people are filing a lawsuit against Bayer and Johnson & Johnson, the manufacturers of Xarelto, for failing to warn about the drug’s dangers.
Why File a Xarelto Lawsuit?
Xarelto is a popular blood thinner that has caused irreversible internal bleeding in some people taking it. This bleeding has led to other serious complications, such as brain damage. In the most severe cases, people have died from taking Xarelto.
Many consumers and their families are taking legal action against the manufacturers of Xarelto. Lawsuits can help recover the costs of medical bills, lost wages and emotional distress. These lawsuits are a means of holding drug manufacturers accountable for their product and providing compensation to their victims.
People are filing personal injury and wrongful death claims against Xarelto’s manufacturers. Many of these cases have moved to multidistrict litigation (MDL).
You may be eligible to file a lawsuit if you believe Xarelto caused any of the following:
- Internal bleeding
- Pulmonary embolism
- Heart attack
- Brain hemorrhage
If you or a loved one developed any severe complications after taking Xarelto, talk to someone who can help you get legal compensation.
Who is Responsible for Xarelto Complications?
Xarelto is a product of Bayer and Johnson & Johnson. Janssen Pharmaceuticals, Inc., a subsidiary of J&J, developed the drug. These manufacturers are being held responsible for the complications caused by Xarelto.
These companies spent millions to promote Xarelto when they began selling it in 2011. Despite the trauma Xarelto caused, sales of the drug continue to mount into the billions of dollars.
Legal Complaints Against Xarelto
People are suing Bayer and Johnson and Johnson (J&J) for failing to fully inform consumers about Xarelto’s risks. In Xarelto lawsuits, plaintiffs claim they weren’t aware the drug could cause irreversible bleeding.
Plaintiffs also say the manufacturers didn’t explain that there is no antidote for Xarelto. This drug can thin the blood to the point where it leaks from blood vessels inside the body.
Because there is no medical solution for bleeding caused by Xarelto, patients have to wait until the drug leaves their system before the bleeding stops. This has led to severe complications in some cases. Uncontrolled internal bleeding can cause cardiac arrest, respiratory failure and death.
Several studies point to the risks of Xarelto in people with kidney problems. Namely, people with kidney disease are more likely to have uncontrollable bleeding while taking Xarelto. Despite these risks, the instances of those people taking the drug has risen.
Doubts About Xarelto
By 2012, the Food and Drug Administration (FDA) had approved Xarelto to treat several conditions. Approved uses of Xarelto include treatment for: atrial fibrillation (AF), deep vein thrombosis (DVT) and pulmonary embolism (PE).
Some reports have brought up concerns about how researchers conducted clinical trials of Xarelto for AF. In its first major trial, Xarelto was compared with warfarin, a blood thinner used for decades. Some reports suggest the results of these trials may be skewed, because doctors offered lower quality treatment with warfarin than with Xarelto.
FDA reviewers said Xarelto warrants “the need for additional data to support approval.” The FDA’s advisory committee has frequently advised against the use of Xarelto for conditions such as acute coronary syndrome.
The number of cases filed against Bayer and J&J have increased as more people have had complications from Xarelto.
In 2015, one woman filed a lawsuit against Bayer and J&J after complications from taking Xarelto. Her complaint stated that the manufacturers neglected to point out the increased risk of bleeding caused by the drug. She suffered severe injuries and sued for compensation for pain and suffering, medical costs and lost wages.
Multidistrict Litigation for Xarelto
Multidistrict litigation consolidates lawsuits from hundreds of plaintiffs suing for similar reasons into a specific district. Many plaintiffs harmed by Xarelto are moving their lawsuits to MDL.
MDL is efficient because judges ruling on the cases are already familiar with the issues. As of May 2015, MDL for Xarelto is taking place in Pennsylvania and Louisiana.
MDL is appropriate for Xarelto cases because there have already been hundreds of lawsuits involving Xarelto with more likely to come.Due to the large amount of lawsuits people are filing, most Xarelto cases become part of multidistrict litigation (MDL).
Getting an Attorney Who Knows Xarelto
Filing a lawsuit is one of the best ways to get compensated for problems caused by Xarelto.
It’s absolutely necessary to hire a lawyer capable of taking on pharmaceutical giants like Bayer and Johnson and Johnson. Experienced lawyers have the resources to represent you and are familiar with handling similar cases.
Last Edited: October 31, 2017
- Knewitz, Mickus. (2012). FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome. May 2016. https://www.jnj.com/news/all/fda-advisory-committee-recommends-against-approval-of-oral-anticoagulant-xarelto-to-reduce-the-risk-of-secondary-cardiovascular-events-in-patients-with-acute-coronary-syndrome
- Heather Isringhausen Gvillo. (2015). 90-count Xarelto lawsuit seeking $4.35M from the drug’s manufacturers removed to MDL court. May 2016. http://madisonrecord.com/stories/510558123-90-count-xarelto-lawsuit-seeking-4-35m-from-the-drug-rsquo-s-manufacturers-removed-to-mdl-court
- The Madison County Record. (2015). Xarelto makers face claims over drug’s alleged inability to timely congeal blood. May 2016. http://madisonrecord.com/stories/510557461-xarelto-makers-face-claims-over-drug-rsquo-s-alleged-inability-to-timely-congeal-blood
- HealthDay News. (2012). FDA Panel Votes Against New Use for Blood Thinner Xarelto. May 2016. http://health.usnews.com/health-news/news/articles/2012/05/24/fda-panel-votes-against-new-use-for-blood-thinner-xarelto
- JESSICA DYE. (2015). MDL Watch: Xarelto, testosterone suits climb in June. May 2016. http://www.reuters.com/article/2015/07/06/products-mdlwatch-june-idUSL1N0ZM0C520150706
- Almashat, Carome, Wolfe. (2011). Public Citizens Health Research Group. May 2016. https://www.citizen.org/documents/1974.pdf